on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Stakes in Avadel Pharmaceuticals
The Vanguard Group, Inc. has filed a Form 8.3 in compliance with the Irish Takeover Panel Act, 1997. The form reveals Vanguard's interests in Avadel Pharmaceuticals plc's securities. As of December 4, 2025, Vanguard holds 5,581,297 US$0.01 ordinary shares, representing a 5.73% stake in the company. This disclosure is mandatory as Vanguard's stake surpasses the 1% threshold required for reporting.
Recent dealings include the purchase of 3,695 shares and sale of 192 shares, each priced at 21.36 USD. The filing indicates no involvement in cash-settled or stock-settled derivative transactions at this time. Additionally, there are no indemnity or option agreements, nor attachments included with this disclosure.
This release is fundamental for stakeholders monitoring changes in ownership stakes in the context of potential future offers or strategic movements concerning Avadel Pharmaceuticals.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news